Physician profile
Graham Brown
NPI 1912385071
$4,678.85
in general payments reported to CMS, 2019-2025
26 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 76% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $21.94 · 2021: $117 · 2022: $1,046 · 2023: $845 · 2024: $672 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,133 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,028.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $688.45 | 2019-2025 | Lynparza |
| Genmab U.S., INC. | $473.38 | 2023-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $406.66 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $342.40 | 2021-2025 | Zejula, Jemperli |
| Eisai INC. | $341.57 | 2024-2025 | |
| Spectrum Pharmaceuticals INC. | $189.62 | 2023-2025 | Rolvedon |
| Myriad Genetic Laboratories, INC. | $176.42 | 2023-2024 | Precisetumor |
| Integra Lifesciences Corporation | $175.03 | 2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Abbvie INC. | $134.55 | 2019-2025 | |
| Tesaro, INC. | $120.75 | 2019 | |
| Seagen INC. | $99.99 | 2025 | |
| Astellas Pharma US INC | $87.98 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $74.83 | 2025 | Enhertu, Datroway |
| Caris Mpi, INC. | $67.74 | 2025 | Mi Cancer Seek |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $45.12 | 2021-2025 | Perclot, Tisseel |
| Pharmaand Gmbh | $39.61 | 2025 | Rubraca |
| Fennec Pharmaceuticals, INC. | $26.92 | 2025 | Fyarro |
| Mylan Institutional INC. | $24.25 | 2023 | Fulphila, Ogivri |
| Tempus Ai, INC | $23.73 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.52 | 2024 | |
| Ethicon US, LLC | $20.82 | 2025 | Enseal |
| Bayer Healthcare Pharmaceuticals INC. | $18.25 | 2019 | |
| Dilon Technologies, INC. | $18.13 | 2025 | Hemoblast Bellows |
| Tela Bio, INC. | $16.96 | 2024 | Ovitex 2s |
| Coherus Oncology, INC. | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graham Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.